AVEXITE Trademark

Trademark Overview

On Monday, November 28, 2005, a trademark application was filed for AVEXITE with the United States Patent and Trademark Office. The USPTO has given the AVEXITE trademark a serial number of 78761772. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 4, 2010. This trademark is owned by Tibotec Pharmaceuticals Ltd.. The AVEXITE trademark is filed in the Pharmaceutical Products category with the following description:

Human pharmaceuticals, namely, anti-infectives, anti-virals, oncologicals, agents for treatment of diseases and disorders of the central nervous system, agents for treatment of inflammatory diseases
avexite

General Information

Serial Number78761772
Word MarkAVEXITE
Filing DateMonday, November 28, 2005
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 4, 2010
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 13, 2007

Trademark Statements

Goods and ServicesHuman pharmaceuticals, namely, anti-infectives, anti-virals, oncologicals, agents for treatment of diseases and disorders of the central nervous system, agents for treatment of inflammatory diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, December 1, 2005
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAVEXA LIMITED
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressRICHMOND, VICTORIA 3121
AU
Party NameTibotec Pharmaceuticals Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCounty Cork
IE
Party NameTibotec Pharmaceuticals Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCounty Cork
IE

Trademark Events

Event DateEvent Description
Monday, January 4, 2010ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, January 4, 2010ABANDONMENT - NO USE STATEMENT FILED
Friday, June 5, 2009EXTENSION 4 GRANTED
Thursday, June 4, 2009EXTENSION 4 FILED
Thursday, June 4, 2009TEAS EXTENSION RECEIVED
Wednesday, December 10, 2008EXTENSION 3 GRANTED
Monday, December 1, 2008EXTENSION 3 FILED
Monday, December 8, 2008CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, December 1, 2008TEAS EXTENSION RECEIVED
Tuesday, June 3, 2008EXTENSION 2 GRANTED
Thursday, May 22, 2008EXTENSION 2 FILED
Thursday, May 22, 2008TEAS EXTENSION RECEIVED
Thursday, December 20, 2007EXTENSION 1 GRANTED
Monday, December 3, 2007EXTENSION 1 FILED
Wednesday, December 5, 2007AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Monday, December 3, 2007TEAS EXTENSION RECEIVED
Tuesday, June 5, 2007NOA MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, April 11, 2007CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Wednesday, April 11, 2007ASSIGNED TO PETITION STAFF
Tuesday, March 13, 2007PUBLISHED FOR OPPOSITION
Thursday, March 1, 2007PAPER RECEIVED
Wednesday, February 21, 2007NOTICE OF PUBLICATION
Friday, January 26, 2007LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, January 24, 2007APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 10, 2007AMENDMENT FROM APPLICANT ENTERED
Wednesday, January 10, 2007CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 10, 2007ASSIGNED TO LIE
Wednesday, December 6, 2006PAPER RECEIVED
Wednesday, June 7, 2006NON-FINAL ACTION E-MAILED
Wednesday, June 7, 2006NON-FINAL ACTION WRITTEN
Wednesday, May 31, 2006ASSIGNED TO EXAMINER
Thursday, December 1, 2005NEW APPLICATION ENTERED IN TRAM

Related Keywords

avexite treatment diseases anti agents central nervous system inflammatory disorders pharmaceuticals